Shiba Inu’s Kusama Strikes Back at Critics, Declares 'Send SHIB to the Moon' Mission Is on Track 
Cardano Hits $1.06 Milestone as Experts Eye $6 and Beyond in Bullish Breakout 
Siri's AI Upgrade in iOS 19 May Signal Apple's Split from OpenAI and ChatGPT 
Crypto Rules Shakeup: Trump-Tied SEC Candidate Hints at Clearer Path After Gensler’s Sudden Exit 
Nvidia CEO: Trump’s AI Export Limits Won’t Halt Global Tech Collaboration 
Xiaomi's Second Electric SUV to Challenge Tesla Model Y in Q1 2025, Report Reveals 
Arthur Hayes Drives Solana Meme Coin Rally, FlowerAI’s Market Cap Jumps $8M After Social Media Post 
Solana Hits $262 ATH Amid $35M Whale Buys—Could $5,000 Be Next? 
Ether Price Rises Despite $1.3B Whale Sell-Off, Targets $3,700 Breakout 
Fed's Goolsbee Expects Rates to Drop 'Fair Bit Lower,' Cautions on Slowing Cuts 
Shiba Inu in Trouble? 33 Trillion SHIB Could Fall If $0.000022 Support Breaks 
Dogecoin Soars 16.8% After Musk’s Alien Meme Shakes Up X: What It Means for Crypto 
Amazon's $4 Billion Anthropic Deal Supercharges AI Race Against Microsoft and Google 
XRP Soars as Trump’s Pro-Crypto Treasury Pick Gains Ripple CEO’s Approval 
AstraZeneca revealed on Tuesday, Dec. 26, that it will buy the China-based biopharmaceutical company Gracell Biotechnologies for up to $1.2 billion. The Anglo-Swedish multinational pharma and biotechnology firm is making this move to achieve its cell therapy ambitions.
According to Reuters, AstraZeneca is also aiming to use the acquisition of Gracell Biotechnologies to boost its presence in China, which is currently the second-largest pharmaceutical market in the world, further.
Payment Terms and Other Acquisition Arrangements
AstraZeneca and Gracell agreed to an all-cash deal for the acquisition. Once the buyout is completed, the former’s portfolio is set to expand with the addition of several experimental therapies.
AstraZeneca is buying the Chinese firm at $2 per ordinary share. This is also equivalent to $10 per American Depository Share of Gracell, which represents a premium of 61.6% based on its Dec. 22 closing.
Merging of Expertise to Achieve Growth and New Biotech Innovation
AstraZeneca and Gracell are looking to combine their respective expertise and resources to develop effective therapies for diseases. They also expect to find new ways of optimizing the therapeutic profile of engineered T cells and take the lead in the next generation of autologous cell therapies.
“The proposed acquisition of Gracell will complement AstraZeneca’s existing capabilities and previous investments in cell therapy, where we have established our presence in CAR-T and T-cell receptor therapies (TCR-Ts) in solid tumors,” AstraZeneca’s executive vice president of Oncology research and development, Susan Galbraith, said in a press release.
She further explained, “GC012F will accelerate our cell therapy strategy in hematology with the opportunity to bring a potential best-in-class treatment to patients living with blood cancers using a differentiated manufacturing process, as well as exploring the potential for cell therapy to reset the immune response in autoimmune diseases.”
Gracell Biotechnologies’ founder, chairman, and chief executive officer, Dr. William Cao, also commented, “We look forward to working with AstraZeneca to accelerate our shared goal of bringing transformative cell therapies to more patients living with debilitating diseases.”
Photo by: Declan Sun/Unsplash
